Pioglitazone Recruiting Phase 2 Trials for Leukemia Acute Myeloid Leukemia (AML) Treatment

IndicationsStatusPurposePhase
RecruitingTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT02942758Low-dose AZA, Pioglitazone, ATRA Versus Standard-dose AZA in Patients >=60 Years With Refractory AML